Upregulation of Nucleotide-Binding Oligomerization Domain-, LRR- and Pyrin Domain-Containing Protein 3 in Motoneurons Following Peripheral Nerve Injury in Mice by Nógrádi, Bernát et al.
Upregulation of Nucleotide-Binding
Oligomerization Domain-, LRR- and
Pyrin Domain-Containing Protein 3 in
Motoneurons Following Peripheral
Nerve Injury in Mice
Bernát Nógrádi1,2†, Ádám Nyúl-Tóth1,3†, Mihály Kozma1,4, Kinga Molnár1,4, Roland Patai1,
László Siklós1, Imola Wilhelm1,5 and István A. Krizbai 1,5*
1Institute of Biophysics, Biological Research Centre, Szeged, Hungary, 2Foundation for the Future of Biomedical Sciences in
Szeged, Szeged Scientists Academy, Szeged, Hungary, 3Department of Biochemistry and Molecular Biology, Vascular Cognitive
Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging/Oklahoma Center for Geroscience,
University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States, 4Theoretical Medicine Doctoral School,
University of Szeged, Szeged, Hungary, 5Institute of Life Sciences, Vasile Goldiş Western University of Arad, Arad, Romania
Neuronal injuries are accompanied by release and accumulation of damage-associated
molecules, which in turn may contribute to activation of the immune system. Since a wide
range of danger signals (including endogenous ones) are detected by the nucleotide-
binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3)
pattern recognition receptor, we hypothesized that NLRP3 may become activated in
response to motor neuron injury. Here we show that peripheral injury of the oculomotor
and the hypoglossal nerves results in upregulation of NLRP3 in correspondingmotor nuclei
in the brainstem of mice. Although basal expression of NLRP3 was observed in microglia,
astroglia and neurons as well, its upregulation and co-localization with apoptosis-
associated speck-like protein containing a caspase activation and recruitment domain,
suggesting inflammasome activation, was only detected in neurons. Consequently,
increased production of active pro-inflammatory cytokines interleukin-1β and
interleukin-18 were detected after hypoglossal nerve axotomy. Injury-sensitive
hypoglossal neurons responded with a more pronounced NLRP3 upregulation than
injury-resistant motor neurons of the oculomotor nucleus. We further demonstrated
that the mitochondrial protector diazoxide was able to reduce NLRP3 upregulation in a
post-operative treatment paradigm. Our results indicate that NLRP3 is activated in
motoneurons following acute nerve injury. Blockade of NLRP3 activation might
contribute to the previously observed anti-inflammatory and neuroprotective effects of
diazoxide.
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INTRODUCTION
Finely tuned interaction between the nervous and the immune
systems and different inflammatory processes play a pivotal role
in the consequences of neuronal injury. The innate immune
system-mediated inflammation can act both as detrimental
(reviewed in Labzin et al., 2018; Schwartz et al., 2016) or
beneficial player after insult to the central nervous system
(CNS) (Raposo et al., 2014), thus may influence the fate of
affected neurons after the lesion. Sensing of potentially
dangerous molecular structures by the innate immune system
relies on pattern recognition receptors (PRRs), whose activation
can lead to the induction of inflammatory processes. PRRs are
mainly expressed in immune cells; however, cellular components
of the CNS, including neurons, have also been demonstrated to
express PRRs.
Ligand recognition by several members of the nucleotide-
binding oligomerization domain (NOD)-like receptor (NLR)
family leads to activation of a multiprotein complex, the
inflammasome, which recruits and activates caspase-1 through
the adaptor molecule apoptosis-associated speck-like protein
containing a CARD (ASC) to proteolytically maturate
interleukin-1 beta (IL-1β) and IL-18 (IL-18). The most
important NLRs in this respect are NOD, leucine rich repeat
and pyrin domain containing (NLRP) 1, nucleotide-binding
oligomerization domain NOD-, LRR- and pyrin domain-
containing protein 3 (NLRP3), and NLR family caspase
activation and recruitment domain (CARD)-containing
domain (NLRC) 4. In addition, absent in melanoma 2 (AIM2)
can also be part of inflammasomes (Latz et al., 2013). Despite an
acknowledged role of inflammation in a large number of CNS
disorders, only a few inflammasomes have been characterized so
far in the CNS. These include NLRP3, NLRP1 and NLRC4
inflammasomes in microglia and astrocytes (Abulafia et al.,
2008; Halle et al., 2008; Hanamsagar et al., 2011; Liu et al.,
2013; Freeman et al., 2017) and NLRP2 inflammasome in
astrocytes (Minkiewicz et al., 2013). In neurons, initially
NLRP1 (Abulafia et al., 2008; de Rivero Vaccari et al., 2008)
and AIM2 (Adamczak et al., 2014) inflammasomes were
described to be activated in response to different stimuli. In
addition, neurons can also express NLRP3 (von Herrmann
et al., 2018) to initiate inflammasome formation (Panicker
et al., 2020), which is by far the most investigated
inflammasome in the CNS. Nowadays it is clear that NLRP3
plays an active role in the pathomechanism of a wide variety of
neurological diseases and aging (Latz et al., 2018; Mészáros et al.,
2020; Heneka et al., 2013), especially in microglia. Much less is
known about regulation of NLRP3 in neurons in response to
acute injury.
In humans, peripheral nerve injuries usually occur in
traumatic accidents and often lead to complications, such as
chronic pain and motor or sensory loss of function (Althagafi and
Nadi 2020). In mice, axotomy is a well-documented and
standardized method to induce motoneuronal injury (e.g.,
Koliatsos and Price 1996). Axonal lesions lead to retrograde
changes in neurons, activation of glial cells and inflammatory
reactions, including extensive microgliosis (Rotterman and
Alvarez 2020). Our goal was to determine whether NLRP3-
mediated processes could occur in response to peripheral
nerve axotomy. Oculomotor and hypoglossal neurons were
selected for our experiments because of the difference in the
neuronal vulnerability and in the inflammatory response to injury
(Obál et al., 2006; Nógrádi et al., 2020).
Mitochondrial dysfunction is a key component and regulator
of NLRP3-mediated inflammasome activation (Liu et al., 2018).
Furthermore, activated NLRP3 may translocate to mitochondria-
associated endoplasmic reticulum membranes, which provide a
platform for NLRP3 inflammasome assembly. On the other hand,
NLRP3 activators induce mitochondrial damage, while NLRP3
directly interacts with molecules released from injured
mitochondria, like cardiolipin, mitochondrial DNA and
reactive oxygen species (Elliott et al., 2018; Zhong et al., 2018).
Therefore, possible effect of diazoxide (7-chloro-3-methyl-4H-
1λ6,2,4-benzothiadiazine 1,1-dioxide), a mitochondrial K+ATP
channel opener and neuroprotective agent, on inflammasome
activation was assessed as well.
MATERIAL AND METHODS
Ethical Considerations
All efforts were made to minimize animal suffering throughout
the experiments, thus multiple surgeries were avoided. All
experiments were carried out in accordance with the
institutional guidelines for the use and care of the
experimental animals and governmental law for animal
protection. The experimental protocols and the animal care
were approved by the institutional care and the Regional
Animal Health and Food Control Station of Csongrád-Csanád
County (permit number: XVI./767/2018 and 03876/0014/2006)
and carried out in accordance with the national law (XXVIII.
chapter IV. paragraph 31) which conforms to the international
laws and policies (EEC Council Directive 86/609, OJL 358 1 DEC.
12, 1987; NIHGuide for the Care and Use of Laboratory Animals,
United States National Research Council, revised 1996).
Experimental Animals and Surgical
Procedures
Balb/c non-transgenic mice (mean body weight of 22 ± 5 g) were
housed in the conventional animal facility of the Biological
Research Center (Szeged, Hungary) for the period of the
experiments. Examinations were performed on 33 young adult
(8–15 week old) male mice, housed in plastic cages (three animals
per cage at most) in a thermoneutral (23 ± 2°C) room under a 12 h
light:dark cycle, with access to regular rodent chow and water ad
libitum.
To avoid multiple surgical procedures on individual animals,
mice were assigned either to eye enucleation (target deprivation)
or hypoglossal nerve axotomy. A total of 30 mice were used for
immunohistochemistry (IHC) quantification. From these
animals, 10 served as non-operated controls (n  5 for the
oculomotor nucleus, n  5 for the hypoglossal nucleus) and 20
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animals underwent either eye enucleation [n  5 (non-treated)]
or hypoglossal nerve axotomy [n  15 (n  5 non-treated, n 
5 diazoxide-treated, n  5 dimethyl sulfoxide/(DMSO)-treated)].
For western blot (WB) evaluation of IL-1β and IL-18 pro-
inflammatory cytokines, surgical unilateral axotomy of the
hypoglossal nerve was conducted on three animals. Surgical
interventions were performed under deep and reversible
anesthesia with Avertin (tribromoethanol, Sigma-Aldrich;
240 mg/kg body weight in a 0.5 ml volume), administered
intraperitoneally. For target deprivation of the oculomotor
nerve, animals were enucleated, the right eyeball, remaining
extraocular muscles and lacrimal gland were removed carefully
from the orbit. In case of hypoglossal axotomy, 1 cm long midline
incision was made below the hyoid bone, the right cranial nerve
XII. was carefully prepared and a 2–3 mm nerve segment was
dissected to prevent regeneration.
For diazoxide treatment, 0.25 mg/ml diazoxide (Sigma-
Aldrich) was dissolved in 10 mg/ml DMSO (Sigma-Aldrich) in
distilled water in a 0.1 ml volume and was administered by
intraperitoneal injection (1 mg/kg bodyweight). DMSO-
treatment was used as vehicle control (10 mg/ml DMSO
dissolved in distilled water, administered intraperitoneally).
Animals received the first dose 3 h after the axotomy, then on
the first, second and third postoperative days (every 24 h,
altogether four doses). On the fourth postoperative day,
animals were sacrificed, thus received no treatment.
Axotomized, non-treated mice received no treatment. All
animals were allowed to survive for 4 days. In each case, the
non-operated side of the motor nucleus served as an internal




Under irreversible anesthesia with Avertin, mice were
transcardially perfused with 10 mM phosphate buffered saline
(PBS; pH 7.4) followed by 4% paraformaldehyde (Sigma-Aldrich)
in 10 mM PBS (pH 7.4). The entire brain was exposed and
removed, then fixed further overnight in the same fixative at
4°C. After the fixation protocol, samples were cryoprotected in
30% sucrose (Sigma-Aldrich) dissolved in 10 mMPBS, for at least
1 day at 4°C. Series of consecutive coronal sections of 30 µm
thickness were cut throughout the whole anatomical regions of
interests with a microtome (Reichert-Jung, Leica Biosystems),
collected in 10 mM PBS individually in wells of tissue culture
plates and stored at 4°C until processed for staining.
IHC stainings were performed on 30 µm thick free-floating
sections. For the quantitative assessment of the changes in
NLRP3, diaminobenzidine tetrahydrochloride (DAB)-based
IHC was used. In both examined motor nuclei, sections (n 
8/each animal) were selected with respect to the anatomical
boundaries. Sections were rinsed (three changes, 5 min each),
then 50%methanol (VWRChemicals) in 10 mMPBS was applied
for tissue permeabilization for 30 min at −20°C. Samples were
rinsed again in 10 mM PBS, then the non-specific staining was
blocked in two steps: 0.6% hydrogen peroxide in 10 mM PBS
containing 0.2% Triton X-100 (Sigma-Aldrich) (TPBS) was used
first for 30 min to block the endogenous peroxidase activity. After
sections were rinsed (three changes, 5 min), the second blocking
step was applied with 2% normal rabbit serum (Vector
Laboratories) in 10 mM TPBS for 1 h. This was followed by
overnight incubation at 4°C with the polyclonal goat primary
antibody against NLRP3 diluted in 10 mM TPBS with 2% normal
rabbit serum. After washing in 10 mM PBS (three changes,
5 min), sections were incubated at room temperature in a
biotinylated rabbit-anti-goat secondary antibody diluted in
10 mM TPBS with 2% normal rabbit serum for 1 h. Next, all
the sections were rinsed in 10 mM PBS (three changes, 5 min
each), incubated in avidin-biotin complex (Vector Laboratories)
diluted to 1:800 in PBS for 1 h at room temperature. After
washing in 10 mM PBS, the reactions were visualized by
incubation in 0.5% DAB (Sigma-Aldrich) with 1.5% NiCl2 in
10 mM PBS for 15 min. Finally, sections were washed in 10 mM
PBS (three changes, 5 min each), mounted on silane-coated glass
slides, covered with Entellan (Merck Millipore) and visualized
under a brightfield microscope (Eclipse 80i, Nikon). Brightness
and contrast were adjusted as needed. To qualitatively evaluate
changes in the level of the inflammasome component ASC, the
IHC procedure was carried out as previously described, with the
difference that serum-specific blocking was performed with 2%
normal goat serum (Jackson Immunoresearch).
Immunofluorescence (IF) staining protocols were also
performed on 30 µm thick free-floating sections. First, selected
sections were rinsed, then 50% methanol was applied, as
previously described. Sections were rinsed again (three
changes, 5 min each), then a blocking step was used with 2%
normal donkey serum (Jackson Immunoresearch) in 10 mM
TPBS for 1 h. Primary antibody cocktails were applied for
overnight incubation at 4°C. The next day, sections were
rinsed (three changes, 5 min each) and secondary antibody
cocktails were used for 1 h. Both the primary and secondary
cocktails were diluted in 10 mM TPBS with 2% normal donkey
serum. Primary and secondary antibody cocktails varied in each
double or triple immunofluorescent staining procedure and are
detailed in Table 1. Finally, sections were washed in 10 mM PBS
(three changes, 5 min each) and, where indicated, Hoechst 33342
(B2261, Sigma-Aldrich) staining was applied (diluted to 1 μg/ml
in 10 mM PBS) to visualize cell nuclei. Sections were mounted on
silane-coated glass slides, covered with Fluoromount-G (0100-01,
Southern Biotechnology Associates) mounting medium.
Secondary antibody staining controls have been carried out for
each of the applied secondary antibodies to exclude the
interference of any associated unspecific staining.
Confocal and Super-ResolutionMicroscopy
Immunofluorescence co-staining was examined with confocal
and super-resolution microscopy (STED) (stimulated emission
depletion) microscopy. Lower resolution imaging was performed
on a Leica SP5 Laser Scanning Microscope (Leica Microsystems),
while super-resolution images were obtained with a STEDYCON
(Abberior Instruments) STED instrument connected to a ZEISS
Axio Observer Z1 inverted microscope. From raw images,
confocal z-stacks were prepared with LAS X viewer and FIJI
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(ImageJ 1.51n engine) software. Some color images are presented
in false color, in order to simplify visualization of certain stainings
by presenting the same target proteins in uniform colors
throughout different images. Brightness and contrast were
adjusted as needed.
Quantitative Evaluation of Light Microscopy
Immunohistochemistry Staining
Quantitative assessment of NLRP3 expression was carried out
with the use of the DAB-based IHC technique, as this method
provides photostability, in contrast to IF. Selection of sections for
staining and evaluation was performed following a systematic
regime. Anatomical boundaries of the nuclei were considered and
eight sections were stained for quantification in each nucleus, in a
way that after a section was selected, the consecutive section was
excluded, to cover more of the anatomical region along the
rostrocaudal axis of the brainstem. The contralateral (control)
side of the samples was marked with a small incision during the
sectioning, thus the injured and control sides could be clearly
distinguished during the evaluation. After staining the series of
the sections, a standardized digital image recording (in a Nikon
Eclipse 80i microscope equipped with a 2,560 × 1,920 pixel
resolution MicroPublisher 5.0 RTV charge-coupled device
camera, QImaging) was conducted on all sections at ×10
magnification, thus both the operated and contralateral
(control) sides of the nucleus were recorded on the same
image. As the first step of the image analysis protocol, a
consistent background subtraction algorithm was applied,
based on internal controls (contralateral side) in each section,
to determine the significantly stained profiles in identical regions
at both the operated and contralateral sides of the nuclei. This was
performed by using an interactive macro developed in our
laboratory (Nógrádi et al., 2020) for the Image-Pro Plus image
analysis software (Media Cybernetics).This resulted in an
automated, unbiased evaluation procedure, since the algorithm
determined the stained profile values with the same background
subtraction for both the injured and contralateral sides on each
section. As the significantly stained partial profile areas were
determined at both sides of the brainstem, the data were
expressed as a percentage, and the algebraic differences
between the operated and the contralateral sides were
determined. These numbers were averaged for the stained
sections, to arrive at a single number characterizing the net
change in the area covered by the significant immunoreaction
induced by the axotomy in each animal.
To quantify the ratio of neurons in which the translocation of
the target protein from the cell nuclei to the cytoplasm could be
observed, a cell-counting procedure was carried out. From the
non-treated axotomized group (hypoglossal axotomy), sections
TABLE 1 | Antibodies used for IHC, IF and WB.
Stainings Primary antibodies Secondary antibodies
NLRP3 (IHC) Polyclonal goat against NLRP3, 1:500 (GTX88190, GeneTex) Biotinylated rabbit anti-goat IgG antibody (H + L), 1:800 (BA-5000,
Vector Laboratories)
ASC (IHC) Monoclonal mouse against ASC, 1:400 (sc-271054, Santa Cruz
Biotechnology)
Biotinylated goat anti-mouse IgG antibody (H + L), 1:800 (BA-
5000, Vector Laboratories)
NLRP3, NeuN (IF) and hoechst Anti-NLRP3, 1:400 Alexa Fluor® 488 cross-adsorbed donkey anti-goat IgG, 1:500
(A-11055, Thermo Fisher Scientific)
Polyclonal mouse against NeuN, 1:500 (MAB377, Millipore) Cy
™
5 AffiniPure donkey anti-mouse IgG (H + L), 1:500
(715–175-150, Jackson Immunoresearch)
NLRP3, ChAT (IF) and hoechst Anti-NLRP3, 1:400 Cy
™
3 AffiniPure donkey anti-goat IgG (H + L), 1:500 (705–165-
003, Jackson Immunoresearch)
Polyclonal rabbit against ChAT, 1:250 (GTX113164, GeneTex) Alexa Fluor® 488 AffiniPure donkey anti-rabbit IgG (H + L), 1:500
(711–545-152, Jackson Immunoresearch)
NLRP3, GFAP (IF) and hoechst Anti-NLRP3, 1:400 Alexa Fluor® 488 donkey anti-goat IgG (H + L), 1:500
Polyclonal rabbit against GFAP, 1:500 (ab7260, Abcam) Alexa Fluor® 546 highly cross-adsorbed donkey anti-rabbit IgG
(H + L), 1:500 (A-10040, Thermo Fisher Scientific)
NLRP3, IBA1 (IF) and hoechst Polyclonal goat against NLRP3, 1:400 (GTX88190, GeneTex) Alexa Fluor® 488 donkey anti-goat IgG (H + L), 1:500
Polyclonal rabbit against IBA1, 1:500 (019–19,741, Wako) Alexa Fluor® 546 donkey anti-rabbit IgG, 1:500
NLRP3 and AQP4 (IF) anti-NLRP3, 1:400 Cy
™
3 donkey anti-goat IgG (H + L), 1:500
Polyclonal rabbit against AQP4, 1:100, (sc-390488, Santa Cruz
Biotechnology)
Alexa Fluor® 647 AffiniPure donkey anti-rabbit IgG (H + L), 1:500
(711-605-152, Jackson Immunoresearch)
NLRP3, GFAP and ASC (IF) Anti-NLRP3, 1:400 Alexa Fluor® 488 cross-adsorbed donkey anti-goat IgG, 1:500
(A-11055, Thermo Fisher Scientific)
Anti-GFAP, 1:500 Alexa Fluor® 546 donkey anti-rabbit IgG, 1:500
Anti-ASC, 1:100 Cy
™
5 donkey anti-mouse IgG, 1:500
IL-1β (WB) Polyclonal goat against IL-1β, 1:500 (AF-401-NA, R&D Systems) HRP-conjugated rabbit anti-goat IgG (H + L), 1:4,000 (A5420,
Sigma-Aldrich)
IL-18 (WB) Polyclonal rabbit against IL-18, 1:500 (5180R-100, BioVision
Incorporated)
HRP-conjugated goat anti-rabbit IgG (H + L), 1:4,000 (111–035-
003, Jackson Immunoresearch)
β-actin (WB) Monoclonal mouse against β-actin, 1:10,000 (A5441, Sigma-
Aldrich)
HRP-conjugated goat anti-mouse IgG (H + L), 1:4,000 (115–035-
003, Jackson Immunoresearch)
NLRP3, nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3; ASC, apoptosis-associated speck-like protein containing a caspase activation and
recruitment domain; IF, immunofluorescence; IHC, immunohistochemistry; WB, western blot; IL-1β; interleukin-1 beta; IL-18, interleukin-18; GFAP, glial fibrillary acidic protein.
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were selected from the hypoglossal nucleus of each animal (n  5
animals). Neuronal cells were recognized based on their size and
the anatomical boundaries. In each of the sections, NLRP3
positive neurons were counted based on the localization of the
staining. If NLRP3 was only present in the neuronal nucleus, the
expression was counted as “nuclear NLRP3.” If NLRP3 staining
was clearly present in the cytoplasm, the expression was counted
as “cytoplasmic NLRP3.” When NLRP3 was clearly present in
both the cytoplasm and nucleus, cells were sorted in the
“cytoplasmic NLRP3” group, since the nuclear NLRP3
expression was recognized as the basal expression and the
cytoplasmic presence of NLRP3 indicated translocation.
Neurons were only counted if a well-described point of
reference (cell nucleus) could be recognized in the section.
Neurons were counted on both the operated and the control
side. The ratio of translocation was determined for each side of
each section and was averaged.
Sample Preparation, Methanol-Chloroform
Precipitation and Western Blot
Under irreversible anesthesia with Avertin, mice were
transcardially perfused with 10 mM PBS. The entire brain was
exposed, removed and placed in 10 mMPBS, then dissected in the
following manner: first, the brain was coronally sliced at
approximately −6 mm from Bregma (at the medulla oblongata
– pons transition), then at -7.5 mm from Bregma (at the
appearance of the decussatio pyramidum). Next, the
cerebellum was carefully dissected and removed from the
sample. From the remaining sample, 1 mm wide lateral
segments were sliced and removed along the sagittal plane on
both sides. From the ventral part of the medulla oblongata, a
0.5 mm wide segment was cut and removed horizontally. Finally,
the sample was sliced along the mid-sagittal axis and the two sides
(injured and control sides) were separated and placed into sample
holders.
Snap-freezing in liquid nitrogen was performed immediately
after tissue dissection, then samples were processed in a Potter-
Elvehjem homogenizer with a PTFE pestle in 10 mM PBS.
Samples were grinded on ice until they were completely
homogeneous. The homogenizer was thoroughly washed
multiple times with distilled water between samples. Samples
were centrifuged twice at 6,000 × g for 8 min at 4°C to remove
debris. An equal volume of methanol and 1/4 volume of
chloroform were added. Samples were vortexed, incubated for
5 min on ice, and centrifuged at 13,000 × g for 5 min at 4°C. After
phase separation, aqueous phase was removed, and protein
samples were washed with ice-cold methanol. Samples were
vortexed and centrifuged again, supernatants were discarded,
and protein pellets were air-dried. Pellets were reconstituted in
2× Laemmli buffer and heated up to 95°C for 5 min. Protein
concentration was determined by using bicinchoninic acid assay
(Thermo Fisher Scientific).
Samples were electrophoresed using standard denaturing SDS/
PAGE and blotted on polyvinylidene difluoride membranes
(0.2 μm pore size; Bio-Rad). After blocking with 3% bovine
serum albumin (BSA) in Tris-buffered saline with 0.1%
Tween-20 (TBS-T), membranes were incubated with primary
antibodies (Table 1) overnight at 4°C. Blots were washed in TBS-
T three times for 10 min, incubated for 1 h in horseradish
peroxidase-conjugated secondary antibodies (Table 1) diluted
in TBS-T, and then washed again in TBS-T. Immunoreaction was
visualized with Clarity Chemiluminescence Substrate (Bio-Rad)
in a ChemiDoc MP System (Bio-Rad). Densitometry analysis was
performed with the Image lab software, version 5.2 (Bio-Rad).
Statistical Analysis of the Data
Student’s t-test was applied to evaluate the differences in NLRP3
translocation from the nucleus to the cytoplasm and the WB
quantification of the active IL-1β and IL-18 levels in the
axotomized and control sides. Differences among the means of
NLRP3 immunostaining was assessed by one-way ANOVA with
Fisher LSD (least significant difference) post-hoc test. All
statistical analysis was performed with R (version 3.6.2; R
Foundation for Statistical Computing) and RStudio integrated
development environment (RStudio). All data are represented as
mean ± SEM. In order to determine the number of animals
needed (sample size: n  5 for IHC and n  3 for WB), power
analysis was carried out with G × Power (Faul et al., 2009).
RESULTS
Expression of Nucleotide-Binding
Oligomerization Domain-, LRR- and Pyrin
Domain-Containing Protein 3 in Motor
Neurons in Response to Target Deprivation
in the Oculomotor Nucleus and Axotomy in
the Hypoglossal Nucleus
First, we assessed NLRP3 expression in the brainstem of animals
exposed to axotomy. According to literature data, in traumatic
brain injury (TBI), the level of inflammasome proteins (NLRP3,
ASC, caspase-1) starts to increase 6 h after injury and peaked at 3
and 7 days (Liu et al., 2013). Furthermore, our previous
experiments demonstrated that microglial activation and
morphological changes, which might correlate with the
inflammatory peak (Fernández-Arjona et al., 2019), show
highest intensity at 4 and 7 days following nerve axotomy
(Paizs et al., 2017; Nógrádi et al., 2020). Thus, in our
experiments, all animals were allowed to survive for 4 days
until the peak immune/inflammatory reaction was observed.
Under control (i.e., non-operated) conditions, there was a
faint basal NLRP3 staining in both sides of the oculomotor and
hypoglossal nuclei in mouse brain sections. Target deprivation in
the case of the oculomotor nucleus led to a significant increase in
the NLRP3 staining which was absent in the contralateral side
serving as an internal control (Figure 1A). Similar changes were
visible in the hypoglossal nucleus after the transection of the
hypoglossal nerve; however, the reaction was more intense
(Figure 1A). Quantitative analysis revealed that increase in
NLRP3 was significant in both the oculomotor nucleus (8.04 ±
1.98 vs. 2.66 ± 0.34%; injured vs. non-operated; p < 0.05) and
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FIGURE 1 | Nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3) protein expression in motor neurons of the
oculomotor and hypoglossal nuclei after specific nerve axotomy. (A) Representative immunohistochemistry stainings of NLRP3 protein on Balb/c mouse brain sections
from the anatomical region of the oculomotor (top panel) and the hypoglossal (bottom panel) nuclei (scale: 100 µm). Corresponding brain nerves were axotomized. (B)
Representative fluorescence immunostaining images of NLRP3, neuronal nuclei (top panel) and choline acetyltransferase (bottom panel) proteins on Balb/c
mouse brain sections from the anatomical region of hypoglossal nucleus after corresponding brain nerve axotomy (scale: 100 µm). Nuclei were counterstained with
Hoechst 33342.
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the hypoglossal nucleus (27.25 ± 4.87 vs.1.13 ± 0.51%; p < 0.0005)
after the nerve transection, when compared to the non-operated
controls. Furthermore, NLRP3 increase was significantly
lower in the oculomotor nucleus compared to the
hypoglossal nucleus following axotomy (8.04 ± 1.98 vs.
27.25 ± 4.87%; injured oculomotor nucleus vs. injured
hypoglossal nucleus; p < 0.0005).
Morphology of the staining suggested that the majority of the
NLRP3-positive cells were neurons. Therefore, we performed co-
stainings with neuronal nuclei (NeuN) and choline
acetyltransferase (ChAT) markers (Figure 1B). We chose the
hypoglossal nucleus because more intense reaction could be
observed compared to the oculomotor nucleus, following
axotomy. NeuN staining decreased in the affected nucleus
compared to its contralateral counterpart reflecting a nucleus-
specific neuronal response to target deprivation, as described by
others (McPhail et al., 2004; Obál et al., 2006). As anticipated, a
significant number of NLRP3-positive cells were NeuN positive as
well (Figure 1B), indicating neuronal upregulation of NLRP3 in
response to target deprivation. ChAT staining almost completely
overlapped with NLRP3 staining, indicating that indeed
motoneurons expressed NLRP3 (Figure 1B). However, at the
side of the lesion, ChAT staining, similarly to NeuN staining,
decreased due to the disturbance in the neuronal homeostasis
(Lams et al., 1988).
In order to identify further cell types that might respond
with the upregulation of NLRP3 to peripheral nerve injury,
we performed co-staining with ionized calcium-binding
adapter molecule 1 (Figure 2A), a microglial marker, and
glial fibrillary acidic protein (GFAP) (Figure 2B), an
astroglial marker. Importantly, the majority of the
microglia were not stained with the NLRP3 antibody, only
a few microglial cells were NLRP3 positive. Similarly, NLRP3
was upregulated only in a small fraction of astrocytes, and
astrocytic endfeet were largely excluded as demonstrated by




Domain-, LRR- and Pyrin
Domain-Containing Protein 3 and
Co-localization With Inflammasome
Component Apoptosis-Associated
Speck-Like Protein Containing a Caspase
Activation and Recruitment Domain
Under control conditions, a significant part of NLRP3 staining
could be seen in the nuclei of neurons. In response to the
transection of the hypoglossal nerve, the staining appeared
mainly in the cytoplasm, in parallel with weakening of the
nuclear staining (Figure 3A). In order to visualize the changes
more accurately and quantitatively, we performed IHC stainings
which confirmed our observations obtained with fluorescence
staining (Figure 3B). Quantitative analysis revealed that the ratio
of neurons showing cytoplasmic NLRP3 was significantly higher
on the injured side of the hypoglossal nucleus following axotomy
(82.24 ± 5.38 vs. 1.95 ± 1.33%; injured side vs. contralateral side;
p < 0.0005) (Figure 3C).
Activation of inflammasomes involves formation of a
multiprotein complex, which includes binding of NLRP3 with
the adaptor molecule ASC. Therefore, we performed co-
localization analysis with the two proteins, and for a better
resolution, we used STED microscopy. Similarly to NLRP3,
ASC was also upregulated after nerve transection in the
hypoglossal nucleus (Figure 4A). Staining performed with
NLRP3 and ASC significantly overlapped mainly in neurons
(Figure 4B). Interestingly, the co-localization could be
observed in the nuclei as well (Figure 4C). Although NLRP3
could be detected in GFAP-positive cells as well, there was almost
no co-localization with ASC (Figure 4C). We could not detect
any co-localization of NLRP3 and ASC in microglial cells either
(data not shown).
Nucleotide-Binding Oligomerization
Domain-, LRR- and Pyrin
Domain-Containing Protein 3
Inflammasome Activation, Interleukin-1
Beta and Interleukin-18 Activation
To examine NLRP3 inflammasome activation, the protein levels
of active IL-1β and IL-18, the main pro-inflammatory cytokines of
the inflammasome pathway, were quantified with WB. These
changes were evaluated in the hypoglossal nucleus following
axotomy of the hypoglossal nerve, since more intense NLRP3
upregulation was observed here compared to the oculomotor
nucleus. Axotomy resulted in a 1.507-fold increase of pro- IL-1β
levels (p < 0.0005), indicative of the priming phenomenon. In
addition, we observed a 1.873-fold increase of the active IL-1β
protein levels in the operated hypoglossal nucleus compared to
the control side (p < 0.05) (Figures 4D,E). Similarly, a 1.893-fold
increase was observed in the active IL-18 levels after axotomy (p <
0.05) (Figures 4D,F).
Inhibition of Nucleotide-Binding
Oligomerization Domain-, LRR- And Pyrin
Domain-Containing Protein 3 Upregulation
by Diazoxide
In order to investigate the role of mitochondrial injury in axotomy-
induced NLRP3 upregulation, we treated experimental animals
post-surgery for 4 days with diazoxide, an agent with proven
neuroprotective effects, able to preserve mitochondrial function
(Teshima et al., 2003). Diazoxide diminished the increase in
NLRP3 expression observed in the non-treated group following
axotomy in the hypoglossal nucleus, compared to the vehicle
control (DMSO), as represented by NLRP3 staining
(Figure 5A) and quantitative analysis (8.49 ± 2.84 vs. 28.49 ±
5.98%; injured + diazoxide vs. injured + vehicle; p < 0.0005)
(Figure 5B). DMSO did not have any significant effect on
axotomy-induced NLRP3 upregulation (Figure 5A,B).
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FIGURE 2 | Partial co-localization of nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3)with glial marker proteins but not
with microvessels on the injured side. (A) Representative confocal super-resolution microscopy (STED) images from fluorescent immunostaining of NLRP3 and ionized
calcium-binding adaptermolecule 1 proteins onBalb/cmouse brain sections from the anatomical region of the hypoglossal nucleus after corresponding brain nerve axotomy.
Nuclei were counterstainedwithHoechst 33342. Top panels: lower magnification (scale: 100 µm); bottompanels: highmagnification (scale: 10 µm). (B)Representative
confocal STED images from fluorescent immunostaining of NLRP3 and glial fibrillary acidic protein proteins on Balb/c mouse brain sections from the anatomical region of the
hypoglossal nucleus after similar brain nerve axotomy. Nuclei were counterstainedwithHoechst 33342. Top panels: lowermagnification (scale: 100 µm); bottompanels: high
magnification (scale: 10 µm). (C) Representative confocal STED images from fluorescent immunostaining of NLRP3 and aquaporin-4 proteins on Balb/c mouse brain
sections from the anatomical region of the hypoglossal nucleus after similar brain nerve axotomy. Top panels: lower magnification (scale: 20 µm); bottom panels: high
magnification (scale: 5 µm). Arrows indicate co-localization of signals.
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DISCUSSION
Elaborate crosstalk between the nervous and the immune systems
modulates a considerable number of pathological processes in the
brain. Accumulating evidence suggests that interaction between
damaged neurons and the immune system, especially the innate
immune system, is pivotal in determining the outcome of
neurological disorders (Trakhtenberg and Goldberg, 2011).
FIGURE 3 | NLRP3 translocation from neuronal cell nuclei into the cytoplasm in response to XII. nerve axotomy. (A) Representative super-resolution microscopy
[nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3)] and confocal (ChAT) images on Balb/c mouse brain sections from
the anatomical region of the hypoglossal nucleus from the non-operated and operated side after hypoglossal nerve axotomy. Top panels (on both the non-operated and
operated sides): lower magnification (scale: 10 µm); bottom panels: high magnification (scale: 5 µm). (B) Representative immunohistochemistry staining images of
NLRP3 protein on Balb/cmouse brain sections from the anatomical region of the hypoglossal nucleus, from the non-operated (left panel) and operated (right panel) sides
after equivalent nerve axotomy (scale: 25 µm). (C) Quantification of intracellular distribution of NRLP3 staining in neurons from non-operated and operated sides of the
hypoglossal nucleus. The graph shows average % ± SEM of neurons in which NLRP3 localized in the nucleus or the cytoplasm (n  5 animals/group, ***  p < 0.0005).
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FIGURE 4 |Co-localization of inflammasome components and production of active interleukin-1 beta (IL-1β) and IL-18 (IL-18) in the XII. nucleus. A) Representative
immunohistochemistry staining images of apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) protein on Balb/c
mouse brain sections from the anatomical region of the hypoglossal nucleus after corresponding brain nerve axotomy (scale: 100 µm). (B) Representative confocal
[nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3)] and super-resolution microscopy (STED) (ASC) images on
Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after hypoglossal nerve axotomy (scale: 10 µm). Solid arrows indicate the co-
localization of NLRP3 and ASC. Dashed arrows indicate NLRP3 without co-localization with ASC. (C) Representative confocal [NLRP3 and glial fibrillary acidic protein
(GFAP)] and STED (ASC) images on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after corresponding brain nerve axotomy (scale:
(Continued )
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Here we demonstrate that after acute lesion, motor neurons
respond with upregulation of NLRP3, an important PRR and
inflammasome component. NLRP3 upregulation and
inflammasome activation have been largely acknowledged
phenomena in CNS diseases (reviewed in Voet et al., 2019);
however, microglia, the innate immune cells of the brain, have
primarily been considered as resident cells involved in
immunological processes of the CNS. Interestingly, in our
model, motor neurons proved to initiate NLRP3 activation,
while microglia were much less involved, despite their
unequivocal role in the pathomechanism of neuronal injury-
induced inflammation. Indeed, other NLRs not tested here, like
NLRP1 or AIM2, may also become upregulated in microglia or
neurons as well in response to axonal injury.
Although our finding that NLRP3 was highly upregulated in
neurons was somehow unexpected, neuronal NLRP3
upregulation and inflammasome activation has already been
detected in a few pathological conditions. For example,
ischemic stroke was shown to activate both NLRP1 and
NLRP3 inflammasomes in neurons through nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)- and
mitogen-activated protein kinase-dependent mechanisms
(Fann et al., 2018). NLRP3 can be a mediator of
inflammatory pain as well: chemical stimulation of the dura
activated NLRP3 inflammasomes mainly in C-type neurons in
the trigeminal ganglion (Chen et al., 2014). Furthermore, in
the SOD1 (G93A) transgenic mice model of amyotrophic
lateral sclerosis (ALS), NLRP3 activation was predominantly
detected in degenerating neurons of the anterodorsal thalamic
nucleus (Debye et al., 2016). Other studies also suggested
activation of NLRP3 in neurons in injury and sterile
inflammation (Chen et al., 2019; Voet et al., 2019).
Nevertheless, in TBI, a mechanical injury model, NLRP3
upregulation was approximately similar in neurons,
astrocytes and microglia (Liu et al., 2013), while in spinal
cord contusion injury, NLRP3 was primarily found in
microglia and neurons (Zendedel et al., 2015). However, to
our best knowledge, inflammasome activation in the CNS after
peripheral nerve injury has been unknown so far.
In our previous study, we have demonstrated that following
acute nerve axotomy, microglia become activated to a different
extent in the different motor nuclei of the brain, depending on the
susceptibility of the respective nucleus to injury in chronic stress
conditions (Nógrádi et al., 2020). For example, in the oculomotor
nucleus, that is known to be resistant to degeneration in ALS,
microglial activation was weaker than in the hypoglossal
nucleus (Nógrádi et al., 2020), which is classically used as a
model region of motoneuronal neurodegeneration in the CNS
(reviewed in Nijssen et al., 2017). However, our current results
indicate that microglial activation does not necessarily lead to
inflammasome activation. This might have functional
consequences, since specific microglia depletion had no
influence on neuronal degeneration and axon regeneration
in another acute nerve injury model (Hilla et al., 2017). On the
other hand, the extent of microglial activation correlated with
the level of motoneuronal NLRP3 upregulation in the two
examined nuclei. Reduced NLRP3 upregulation after axotomy
in the oculomotor nucleus compared to the hypoglossal
nucleus might be coupled to the improved ionic buffering
capacity of oculomotor neurons, especially to their ability to
control calcium accumulation in mitochondria (Obál et al.,
2006).
Under control conditions, we observed a strong NLRP3
staining in the cell nuclei. In response to nerve injury, NLRP3
was not only upregulated, but also translocated to the cytoplasm
of motoneurons. Increased production of active IL-1β and IL-18
on the side of the injury suggests activation of inflammasomes,
since cleavage of these cytokines is one of the best readout
parameters of inflammasome activity (Broz and Dixit 2016; He
et al., 2016; Zheng et al., 2020). Although the classical site of
assembly of inflammasomes is the cytoplasm, a recent study
revealed that six out of the 20 examined NLRs were detected in
the nucleus as well. These include NLRP1, NLRP3, NLRP5,
NLRP6, NLR family acidic transactivating domain (NLRA)
and NLRC5 (Wang et al., 2016). Although we could clearly
detect translocation of NLRP3 from the nucleus to the
cytoplasm after nerve injury, a faint NLRP3 signal could still
be detected in the nucleus, co-localized with ASC. Importantly, in
certain cases, inflammasomes can be activated in the nucleus as
well. Nuclear activation of interferon gamma-inducible protein
16 (IFI16) inflammasome could be detected during Kaposi
sarcoma-associated herpesvirus infection in endothelial cells
(Kerur et al., 2011). In the nucleus, activated caspase-1 may
have other substrates than pro-IL-1β and pro-IL-18, e.g., sirtuin-
1. Besides participating in the formation of inflammasomes,
nuclear NLRs may have other functions as well, e.g., NLRP3 is
a transcriptional regulator in T helper type 2 cells and a repressor
of regulatory T cell differentiation (Bruchard et al., 2015; Park
et al., 2020). It is not known yet, whether beyond serving as a
receptor in inflammasomes, NLRP3 has any regulatory functions
in neurons.
Several therapeutic approaches have proved that inhibition of
the NLRP3 pathway could successfully prevent or slow down
neuronal loss in neurodegenerative disorders (Zhou et al., 2016;
Dempsey et al., 2017; Gordon et al., 2018). Based on this,
reduction of NLRP3 activation seems to be a promising point
FIGURE 4 | 10 µm). Solid arrows indicate co-localization of NLRP3 and ASC in the nucleus and cytoplasm of the cells. Dashed arrow indicates co-localization of NLRP3
with GFAP, but not with ASC. (D) Representative western blot images of IL-1β and IL-18 proteins in of the hypoglossal nuclei after unilateral axotomy of corresponding
brain nerve. Arrows indicate pro-forms, arrowheads show active cytokines. (E) Quantification of pro- and active IL-1β expression based on the western blot analysis of
the hypoglossal nuclei in n  3 animals. The graph shows values normalized to β-actin levels and to control side (average ± SEM,*  p < 0.05; ***  p < 0.0005). (F)
Quantification of active IL-18 expression based on the western blot analysis of the hypoglossal nuclei in n  3 animals. The graph shows values normalized to β-actin
levels and to control side (average % ± SEM, *  p < 0.05).
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of intervention in acute injury conditions as well. Diazoxide, an
activator of the mitochondrial ATP-dependent K+ channel,
which readily crosses the blood-brain barrier, is known to
reduce mitochondrial dysfunction (Domoki et al., 2004) and
to protect neurons during ischemia/reperfusion injury (Lei
et al., 2018). Opening of mitochondrial K+ATP channels results
also in activation of anti-apoptotic mechanisms in neurons (Liu
et al., 2002).
Diazoxide could also block microglial activation and reduce
mitochondrial swelling in neurons following nerve axotomy in
our previous experiments (Nógrádi et al., 2020). Interestingly,
such effect on microglial mitochondrial morphology was not
observed. Furthermore, diazoxide could reduce NLRP3 activation
during cerebral ischemia/reperfusion injury through protecting
mitochondria (Zhe et al., 2018; Gong et al., 2018). Indeed,
mitochondrial dysfunction has a pivotal role in initiation and
activation of the NLRP3 inflammasome (Liu et al., 2018), thus the
ability of diazoxide to reduce neuronal mitochondrial injury
could be a major pathway in dampening NLRP3 upregulation
following acute nerve injury.
In our acute nerve injury model, diazoxide was able to
block NLRP3 increase in a post-surgery treatment paradigm.
As the neuroprotective effect of diazoxide has already been
established (Lei et al., 2018), our results raise the point
whether blockade of NLRP3 increase might act as a
contributing factor to the neuroprotective properties of
diazoxide in acute nerve injury. Also, as diazoxide could
dampen the axotomy-induced microgliosis, it is possible
that this effect, at least in part, could be mediated through
the reduction of mitochondrial injury and NLRP3 activation.
Therefore, our observation further strengthens the
significance of the anti-inflammatory properties of
diazoxide from a therapeutic point of view.
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